Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Bone targeted therapy in breast cancer: present and future
Huober J, Thürlimann B. Bone targeted therapy in breast cancer: present and future. Crit Rev Oncol Hematol 2010; 74S1:S7-S10.
01.04.2010Bone targeted therapy in breast cancer: present and future
01.04.2010Crit Rev Oncol Hematol 2010; 74S1:S7-S10
Huober Jens, Thürlimann Beat
[Breast cancer: screening, treatment and follow-up]
Hasler-Strub U, Moos R. [Breast cancer: screening, treatment and follow-up]. Praxis (Bern 1994) 2010; 99:413-8.
31.03.2010[Breast cancer: screening, treatment and follow-up]
31.03.2010Praxis (Bern 1994) 2010; 99:413-8
Hasler-Strub Ursula, Moos R von
Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer
Retèl V, Joore M, Knauer M, Linn S, Hauptmann M, Harten W. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer 2010; 46:1382-91.
30.03.2010Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer
30.03.2010Eur J Cancer 2010; 46:1382-91
Retèl Valesca P, Joore Manuela A, Knauer Michael, Linn Sabine C, Hauptmann Michael, Harten Wim H van
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
von Minckwitz G, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Untch M. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010; 28:2015-23.
22.03.2010Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
22.03.2010J Clin Oncol 2010; 28:2015-23
von Minckwitz Gunter, Kühn Thorsten, du Bois Andreas, Blohmer Jens-Uwe, Thomssen Christoph, Dan Costa Serban, Jackisch Christian, Kaufmann Manfred, Mehta Keyur, Hanusch Claus, Gerber Bernd, Rezai Mahdi, Loibl Sibylle, Fasching Peter A, Huober Jens, Tesch Hans, Bauerfeind Ingo, Hilfrich Jörn, Eidtmann Holger, Untch Michael
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
Untch M, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, von Minckwitz G. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28:2024-31.
22.03.2010Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
22.03.2010J Clin Oncol 2010; 28:2024-31
Untch Michael, Kühn Thorsten, du Bois Andreas, Blohmer Jens-Uwe, Thomssen Christoph, Dan Costa Serban, Jackisch Christian, Kaufmann Manfred, Mehta Keyur, Hanusch Claus, Gerber Bernd, Rezai Mahdi, Loibl Sibylle, Fasching Peter A, Huober Jens, Tesch Hans, Bauerfeind Ingo, Hilfrich Jörn, Eidtmann Holger, von Minckwitz Gunter
Radiation Recall Reaction
Jungi M, Rothermundt C. Radiation Recall Reaction. Schweizerisches Medizin-Forum 2010; 10:255.
21.03.2010Radiation Recall Reaction
21.03.2010Schweizerisches Medizin-Forum 2010; 10:255
Jungi Manuel, Rothermundt Christian
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
Knauer M, Linn S, Bueno-de-Mesquita J, Koornstra R, van de Vijver M, Hauptmann M, Bender R, Rutgers E, Mook S, van 't Veer L. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010; 120:655-61.
05.03.2010The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
05.03.2010Breast Cancer Res Treat 2010; 120:655-61
Knauer Michael, Linn Sabine C, Bueno-de-Mesquita Jolien M, Koornstra Rutger H T, van de Vijver Marc J, Hauptmann Michael, Bender Richard A, Rutgers Emiel J T, Mook Stella, van 't Veer Laura J
[Glioblastoma Multiforme - New Hope due to Modern Therapeutical Approaches.]
Gautschi O, Cadosch D, Collen T, Land M, Hoederath P, Hildebrandt G, Fournier J, Hundsberger T. [Glioblastoma Multiforme - New Hope due to Modern Therapeutical Approaches.]. Praxis (Bern 1994) 2010; 99:295-308.
03.03.2010[Glioblastoma Multiforme - New Hope due to Modern Therapeutical Approaches.]
03.03.2010Praxis (Bern 1994) 2010; 99:295-308
Gautschi Oliver, Cadosch D, Collen T D, Land M, Hoederath Petra, Hildebrandt Gerhard, Fournier Jean-Yves, Hundsberger Thomas
Evolving classification systems for cancer cachexia: ready for clinical practice?
Blum D, Omlin A, Fearon K, Baracos V, Radbruch L, Kaasa S, Strasser F, European Palliative Care Research Collaborative. Evolving classification systems for cancer cachexia: ready for clinical practice?. Support Care Cancer 2010; 18:273-9.
01.03.2010Evolving classification systems for cancer cachexia: ready for clinical practice?
01.03.2010Support Care Cancer 2010; 18:273-9
Blum David, Omlin Aurelius, Fearon Ken, Baracos Vickie, Radbruch Lukas, Kaasa Stein, Strasser Florian, European Palliative Care Research Collaborative
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
Paridaens R, Coates A, Crivellari D, Holmberg S, Price K, Thürlimann B, Gelber R, Cole B, Gelber S, Goldhirsch A. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 2010; 123:303-10.
27.02.2010Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
27.02.2010Breast Cancer Res Treat 2010; 123:303-10
Paridaens Robert J, Coates Alan S, Crivellari Diana, Holmberg Stig B, Price Karen N, Thürlimann Beat, Gelber Richard D, Cole Bernard F, Gelber Shari, Goldhirsch Aron
Die Glykogenose Typ II
Hundsberger T, Erdelyi B, Hohl U, Rösler K. Die Glykogenose Typ II - Morbus Pompe. S C H W E I Z E R A R C H I V F Ü R N E U R O L O G I E U N D P S Y C H I A T R I E 2010; 161:55-59.
26.02.2010Die Glykogenose Typ II
26.02.2010S C H W E I Z E R A R C H I V F Ü R N E U R O L O G I E U N D P S Y C H I A T R I E 2010; 161:55-59
Hundsberger Thomas, Erdelyi Barbara, Hohl Ursula, Rösler Kai Michael
Geographic variation in breast cancer care in Switzerland
Ess S, Savidan A, Frick H, Rageth C, Vlastos G, Lütolf U, Thürlimann B. Geographic variation in breast cancer care in Switzerland. Cancer Epidemiol 2010; 34:116-21.
24.02.2010Geographic variation in breast cancer care in Switzerland
24.02.2010Cancer Epidemiol 2010; 34:116-21
Ess S, Savidan A, Frick H, Rageth Ch, Vlastos G, Lütolf U, Thürlimann Beat
Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience
Gillessen Sommer S, Powles T, Lim L, Wilson P, Shamash J. Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience. Ann Oncol 2010; 21:1589-93.
17.02.2010Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience
17.02.2010Ann Oncol 2010; 21:1589-93
Gillessen Sommer Silke, Powles T, Lim L, Wilson P, Shamash J
Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue
Antonov J, Aebi S, Altermatt H, Viale G, Giobbie-Hurder A, Thürlimann B, Oberli A, Baltzer A, Wirapati P, Delorenzi M, Popovici V, Jaggi R. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC cancer 2010; 10:37.
09.02.2010Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue
09.02.2010BMC cancer 2010; 10:37
Antonov Janine, Aebi Stefan, Altermatt Hans Jorg, Viale Giuseppe, Giobbie-Hurder Anita, Thürlimann Beat, Oberli Andrea, Baltzer Anna, Wirapati Pratyaksha, Delorenzi Mauro, Popovici Vlad, Jaggi Rolf
Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer
Huober J, Schoch O, Templeton A, Spirig C, Thürlimann B. Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer. Chemotherapy 2010; 56:69-70.
08.02.2010Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer
08.02.2010Chemotherapy 2010; 56:69-70
Huober Jens, Schoch Otto, Templeton Arnoud, Spirig Christian, Thürlimann Beat
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
Jörger M, Huitema A, Krähenbühl S, Schellens J, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri A. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102:673-7.
02.02.2010Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
02.02.2010Br J Cancer 2010; 102:673-7
Jörger Markus, Huitema A D R, Krähenbühl S, Schellens J H M, Cerny Thomas, Reni M, Zucca E, Cavalli F, Ferreri A J M
Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature
Mook S, Knauer M, Bueno-de-Mesquita J, Retèl V, Wesseling J, Linn S, Van't Veer L, Rutgers E. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 2010; 17:1406-13.
22.01.2010Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature
22.01.2010Ann Surg Oncol 2010; 17:1406-13
Mook Stella, Knauer Michael, Bueno-de-Mesquita Jolien M, Retèl Valesca P, Wesseling Jelle, Linn Sabine C, Van't Veer Laura J, Rutgers Emiel J
Current multiple myeloma treatment strategies with novel agents: a European perspective
Ludwig H, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Hess U, Harousseau J, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Zweegman S. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010; 15:6-25.
19.01.2010Current multiple myeloma treatment strategies with novel agents: a European perspective
19.01.2010Oncologist 2010; 15:6-25
Ludwig Heinz, Ketterer Nicolas, Kropff Martin, Mendeleeva Larisa, Morgan Gareth, Palumbo Antonio, Plesner Torben, San Miguel Jesús, Shpilberg Ofer, Sondergeld Pia, Sonneveld Pieter, Hess Urs, Harousseau Jean-Luc, Beksac Meral, Bladé Joan, Boccadoro Mario, Cavenagh Jamie, Cavo Michele, Dimopoulos Meletios, Drach Johannes, Einsele Hermann, Facon Thierry, Goldschmidt Hartmut, Zweegman Sonja
Erstes Symposium für Integrative Onkologie und Forschung in der Schweiz
Wolf U, Heusser P, Cerny T, Schlaeppi M. Erstes Symposium für Integrative Onkologie und Forschung in der Schweiz. Swiss Journal of Integrative Medicine 2010:34-35.
18.01.2010Erstes Symposium für Integrative Onkologie und Forschung in der Schweiz
18.01.2010Swiss Journal of Integrative Medicine 2010:34-35
Wolf Ursula, Heusser Peter, Cerny Thomas, Schlaeppi Marc
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
Schaub F, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda R. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010; 115:2003-7.
08.01.2010Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
08.01.2010Blood 2010; 115:2003-7
Schaub Franz X, Looser Renate, Li Sai, Hao-Shen Hui, Lehmann Thomas, Tichelli André, Skoda Radek C